A recent study demonstrated that YLT-11 (a novel Plk4 inhibitor) treatment caused abnormal centriole numbers and defective mitosis in BC cells, especially for triple-negative breast cancer (TNBC) cells. The gene discussed is PLK4; the disease is breast cancer.